Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
CA 2372947 C · Owner: Astrazeneca Pharmaceuticals Lp · Inventors: Ehlers, Mario R. W.; Coolidge, Thomas R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Individuals in need of treatment of ischemia-related reperfusion are treated preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 27, 2000 and granted February 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.